

Article

# GDF6 Knockdown in a Family with Multiple Synostosis Syndrome and Speech Impairment

Raymond A. Clarke <sup>1,\*</sup>, Zhiming Fang <sup>1</sup>, Dedee Murrell <sup>2</sup>, Tabrez Sheriff <sup>2</sup> and Valsamma Eapen <sup>1</sup> 

<sup>1</sup> Ingham Institute, School of Psychiatry, University of NSW, Sydney, NSW 2170, Australia; z.fang@alumi.unsw.edu.au (Z.F.); v.eapen@unsw.edu.au (V.E.)

<sup>2</sup> School of Medicine, St George Hospital, University of NSW, Sydney, NSW 2217, Australia; d.murrell@unsw.edu.au (D.M.); tabrez.sheriff@gmail.com (T.S.)

\* Correspondence: r.clarke@unsw.edu.au

**Abstract:** Multiple synostoses syndrome type 4 (SYNS4; MIM 617898) is an autosomal dominant disorder characterized by carpal-tarsal coalition and otosclerosis-associated hearing loss. SYNS4 has been associated with GDF6 gain-of-function mutations. Here we report a five-generation SYNS4 family with a reduction in GDF6 expression resulting from a chromosomal breakpoint 3' of GDF6. A 30-year medical history of the family indicated bilateral carpal-tarsal coalition in ~50% of affected family members and acquired otosclerosis-associated hearing loss in females only, whereas vertebral fusion was present in all affected family members, most of whom were speech impaired. All vertebral fusions were acquired postnatally in progressive fashion from a very early age. Thinning across the 2nd cervical vertebral interspace (C2-3) in the proband during infancy progressed to block fusion across C2-7 and T3-7 later in life. Carpal-tarsal coalition and pisiform expansion were bilaterally symmetrical within, but varied greatly between, affected family members. This is the first report of SYNS4 in a family with reduced GDF6 expression indicating a prenatal role for GDF6 in regulating development of the joints of the carpals and tarsals, the pisiform, ears, larynx, mouth and face and an overlapping postnatal role in suppression of aberrant ossification and synostosis of the joints of the inner ear (otosclerosis), larynx and vertebrae. RNAseq gene expression analysis indicated >10 fold knockdown of *NOMO3*, *RBMXL1* and *NEIL2* in both primary fibroblast cultures and fresh white blood cells. Together these results provide greater insight into the role of GDF6 in skeletal joint development.

**Keywords:** multiple synostosis syndrome; vertebral fusion; GDF6; SYNS4; Klippel-Feil; progressive ossification; pisiform; skeletal morphology



**Citation:** Clarke, R.A.; Fang, Z.; Murrell, D.; Sheriff, T.; Eapen, V. GDF6 Knockdown in a Family with Multiple Synostosis Syndrome and Speech Impairment. *Genes* **2021**, *12*, 1354. <https://doi.org/10.3390/genes12091354>

Academic Editors: Michele Cioffi and Maria Teresa Vietri

Received: 22 July 2021

Accepted: 26 August 2021

Published: 29 August 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Bone morphogenetic proteins (BMPs) regulate skeletal development, bone morphology and joint formation. Joints form when skeletal elements segment and develop articulations that provide flexibility, strength and versatility through specialised functions and appendages [1]. Much of what we now know regarding the molecular basis of skeletal joint development derives from our understanding of genetic changes affecting *BMP13* and *BMP14*, more commonly referred to as growth and differentiation factor 6 (*GDF6*) and 5 (*GDF5*), respectively [1–5].

GDF6 joint phenotypes overlap GDF5 joint phenotypes, including carpal, tarsal and vertebral fusion [6–8]. GDF5 gain-of-function mutations increase the downstream signalling of GDF5 causing proximal symphalangism (SYM) and multiple synostoses syndrome type 2 (SYNS2; MIM 610017) which is characterised by the fusion of the carpals, tarsals and vertebrae [6–8]. By comparison, GDF5 loss-of-function mutations cause brachydactyly (BDA and BDC) [8,9]. GDF6 gain-of-function mutations cause multiple synostoses syndrome type 4 (SYNS4) [3–5] which is characterised by synostoses of the carpals and tarsals and otosclerosis-associated conductive hearing loss but not vertebral fusion [3–5].



**Table 1.** Clinical details of selected family members.

Family Member	Sex	Ages	Anomalies
Proband (IV-12)	F	0–27	Carpal Tarsal Coalition, Pisiform elongated No hearing impairment or congenital vertebral fusion, Postnatal vertebral fusion, speech impaired, short tongue and microstomia.
Brother (IV-10)	M	7–26	Carpal Tarsal Coalition, Pisiform elongated No hearing impairment or congenital vertebral fusion, Postnatal vertebral fusion, No speech impairment, short tongue and microstomia.
Brother (IV-9)	M	12–19	Carpal Tarsal Coalition, Pisiform elongated No hearing impairment, Postnatal vertebral fusion, Severe speech impairment, short tongue and microstomia.
Cousin (IV-5)	M	17–50	Carpal Tarsal Coalition, Pisiform not tested No hearing impairment, Progressive vertebral fusion, Severe speech impairment, short tongue and microstomia.

Comparative rtPCR: First-strand cDNA synthesis was performed using the SuperScript™ III First-Strand synthesis rtPCR Kit (Invitrogen Cat# 11752-050, Thermo Fisher Scientific, Sydney, Australia) according to manufacturers' instructions: 10 µL of 2 × RT Reaction Mix, 2 µL RT Enzyme Mix and 50 pg of purified RNA were made up to 20 µL with DEPC-treated water and incubated at 25 °C for 10 min and again at 42 °C for 50 min. Reactions were terminated at 85 °C for 5 min, then chilled on ice for 5 min followed by a short spin in the microfuge. Then 1 µL (2 U) of E. coli RNase H was added and incubated at 37 °C for 20 min.

PCR master mix was prepared from a common stock reaction mix. Volumes for a 25 µL reaction were as follows: 12.5 µL of Platinum® SYBR® Green qPCR SuperMix-UDG (#11733-046 Thermo Fisher Scientific, Sydney, Australia.), 1 µL each of 10 µM primer stocks specific for the genes of interest (Table 2), 2.5 µL of cDNA and DEPC-treated water to 25 µL. Reactions were incubated at 50 °C for 2 min and an initial denaturation step of 94 °C for 2 min. PCR was performed for 40 cycles with denaturation at 94 °C for 15 sec, annealing at 55 °C for 10 sec and extension at 72 °C for 20 sec. Comparative PCR profiles were independently normalised against the expression of two house-keeping genes (*GAPDH* and *18sRNA*) to remove any non-biological variation.

**Table 2.** PCR Primers.

Primer Direction	Primer Sequence
<i>GDF6</i> —forward	CCTGTIGCTIGTTTGGTTCA
<i>GDF6</i> —reverse	GCTGTCCATTTCTCTTTGC
<i>18S rRNA</i> —forward	GTAACCCGTTGAACCCATT
<i>18S rRNA</i> —reverse	CCATCCAATCGGTAGTAGCG
<i>GAPDH</i> —forward	CCACCCATGGCAAATTCATGGCA
<i>GAPDH</i> —reverse	TCTAGACGGCAGGTCAGGTCCACC
Stealth control—sense	CAAGAACAGCGAGAAGCAGCCGUCA
Stealth control—antisense	UGACGGCUGCUUCUCGUGUUCUUG

mRNA sequencing by Illumina HiSeq /Novaseq: Total RNA of each sample was extracted using TRIzol Reagent and Purelink RNA mini kit columns. Total RNA of each sample was quantified and qualified by an Agilent 2100/2200 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA), NanoDrop (Thermo Fisher Scientific, Sydney, Australia). 1 µg total RNA was used for library preparation. Next generation sequencing library preparations were constructed according to the manufacturer's protocol by Genewiz China.

Differential expression analysis used the DESeq2 Bioconductor package, a model based on the negative binomial distribution. The estimates of dispersion and logarithmic fold changes incorporate data-driven prior distributions, Padj of genes were set  $<0.05$  to detect differentially expressed genes. For expression analysis transcripts in Fasta format were converted from known gff annotation file and indexed properly. Then, with this file as a reference gene file, HTSeq (v0.6.1) estimated gene and isoform expression levels from the pair-end clean data. For GO and KEGG enrichment analysis GOSec (v1.34.1) was used to identify Gene Ontology (GO) terms that annotate a list of enriched genes with a significant padj  $< 0.05$ . TopGO was used to plot DAG. Differentially expressed genes are presented in order of fold change relative to unaffected control.


### 3. Results

#### 3.1. Radiological Review

This is the first long-term review of a SYNS4 family. We review a 30-year history of radiological films and reports for the affected family (Figure 1) where ~50% of the affected displayed carpal and tarsal coalition, all affected family members displayed expansion of the pisiform and six of the seven affected females tested presented with otosclerosis-associated conductive hearing loss that was absent from affected males. All affected family members presented with variable degrees of vertebral fusion and most were speech impaired.

##### 3.1.1. Female Proband (IV-12)


The female proband presented with bilateral carpal and tarsal coalition. In the feet there was bilateral fusion between the navicular and cuboid. In the hands there was bilateral fusion between the triquetrum and lunate and between the hamate and capitate and partial fusion between the hamate and pisiform (Figure 2). Bilateral elongation of the pisiforms was symmetrically similar in the proband (Figure 3a) and all other affected family members tested, but varied greatly in degree between affected family members (Figure 3b). Pisiform elongation associated with restricted wrist rotation/supination and grasping and capacity to write. Prenatal ultrasound of the proband provided no evidence of vertebral fusion (Figure 4a). Spinal radiographs at age 10 weeks for the proband confirmed the absence of congenital vertebral fusion in the cervical spine (Figure 4b). At age 12 months the proband had developed fusion of the C2-3 apophyseal joints and anterior regions of the spinous processes (Figure 4c). At age 13 there was complete fusion of the C2-3 vertebral bodies, fusion of the anterior edges of C3-4 and C4-5 vertebral bodies, progressive ossification of the anterior edges between C5-6 vertebral bodies, partial fusion of the apophyseal joints and spinous processes at C6-7 (Figure 4d) and partial fusion of T3-7 vertebral bodies. At age 27 spinal fusion of the vertebrae had progressed to form block fusion across C2-7 (Figure 4e) and a continuous set of partial fusions of the anterior edges of the vertebral bodies between T3-T7 (Figure 4f). The bilaterally elongated pisiforms of the proband did not increase in length or size over time nor did the fusion of carpals or tarsals appear to progress. Pisiform elongation was associated with restricted flexion and supination movement of the wrist. The proband presented with stiffness in the Achilles tendon with associated toe walking. She was the only female (age 27) tested that was negative for hearing loss and she was dysphonic from birth and displayed severe speech impairment which was associated with malformation of laryngeal cartilages in her speech-impaired father. Short tongue and microstomia was evident in the proband and most other affected family members in association with overcrowding of the teeth that required teeth removal.



**Figure 2.** Radiographs of proband's wrist highlighting: (a) Fusion of lunate and triquetrum (large white arrow), nearly complete fusion of hamate and pisiform (small white arrow) and elongation of the pisiform (black arrow). (b) Elongated pisiform (large white arrow) and fusion of hamate and pisiform (small white arrow).



**Figure 3.** Radiographs of wrists of: (a) Proband—display bilateral symmetry of elongation of the pisiforms. (b) Proband's father—displays bilateral symmetry of elongation of the pisiforms which are different in length and morphology from those of the proband. Both father and daughter had restricted wrist rotation/supination and grasping and writing capacity.



**Figure 4.** Radiological review of family. Legend: (a) Prenatal ultrasound of cervical spine of proband 36 Weeks; (b) Radiographs of cervical spine of proband age 10 weeks, (c) 12 months (d) 13 years (e) 27 years; (f) Radiograph of thoracic spine of proband age 27 years; (g) Radiograph of cervical spine of brother IV-10 age 7 years, (h) age 14 years, (i) age 17 years, (j) age 26 years; (k) Radiograph of thoracic spine of IV-10 age 17 years, (l) age 26 years, (m) father III-6; (n) Radiograph of cervical spine of brother IV-9 age 12 years, (o) age 19 years, (p) cousin IV-5 age 17 years, (q) age 24 years; (r) Bilateral deviation of the proximal phalanges cousin IV, (s) aunt III-2, (t) Bilateral spurs on patella Aunt III-5 age 65 years.

### 3.1.2. Brother (IV-10)

The youngest brother of the proband presented with bilateral fusion between the hamate and capitate and between the hamate and pisiform, but not between the lunate and triquetrum as observed in both the proband and her affected father. In addition, there was bilateral extension of the pisiform proximally that restricted supination of the wrists and apposition of the thumbs. There was bilateral fusion of the tarsals including cuneiform coalition and talocalcaneal coalition. Radiographs of the spine indicated progressive postnatal cranio-caudal acquisition of vertebral fusions beginning from C2-3. At age 7 this boy presented with fusion of the apophyseal joints and spinous processes of the 2nd and 3rd cervical (C2-3) vertebrae (Figure 4g) which by age 14 had progressed to complete fusion of the C2-3 vertebral bodies and thinning of the vertebral interspace at C3-4 (Figure 4h). At age 17 ossification of intervertebral disc spaces had progressed to where there was thinning of the C3-7 vertebral interspaces and fusion of the apophyseal joints at C2-6 on the right and C6-7 on the left (Figure 4i) which by age 26 had progressed to complete block fusion of C2-7 (Figure 4j). At age 26 he presented with vertebral fusion in the upper thoracic spine where there had only been thinning of these interspaces 9 years earlier (Figure 4k). At age 26 there was partial anterior fusion of the vertebral bodies at T4-T6 (Figure 4l) comparable to the thoracic fusion profile in the spine of his affected father III-6 (Figure 4m). Aged 7 years, he presented with very mild dysphonia, habitual toe walking, severely restricted flexion and supination movement in the hands, microtia, low set ears, short tongue, microstomia and overcrowding of the teeth that required teeth removal. Mobility of other joints appeared normal and there was no conductive hearing loss evident in this man or any other affected male member of the family.

### 3.1.3. Brother (IV-9)

The proband's oldest brother (IV-9) presented with postnatal fusion in the cervical spine which progressed in a cranio-caudal direction from C2-3. A solitary C2-3 fusion identified at age 12 (Figure 4n) had progressed 7 years later to include a C4-5 fusion

and thinning of the C6-7 interspace (Figure 4o). There was no evidence of conductive hearing loss in this brother or any other affected male members of the family. He suffered severe dysphonia from birth associated with severe speech impairment, microstomia and overcrowding of the teeth.

#### 3.1.4. Male Cousin (IV-5)

The proband's male cousin (IV-5) presented with progressive postnatal fusion of the cervical spine. Fusion of the C2-3, C4-5 and C6-7 cervical vertebrae at age 17 (Figure 4p) had progressed to C2-7 block fusion at age 24 (Figure 4q). At age 50 he experienced severe stiffness of the neck, shoulders and back. There was no evidence of conductive hearing loss. Severe speech impairment was evident from an early age. Short tongue and microstomia was associated with overcrowding of the teeth that required removal of eight teeth from him and all three of his affected sisters (IV-6, -7 and -8).

#### 3.1.5. Familial Skeletal Anomalies


Near 50% of affected family members tested presented with variable degrees of carpal and tarsal coalition. Carpal and tarsal fusions were bilaterally similar in extent and morphology within affected family members but varied between affected family members. Likewise, expansion of the pisiform was bilaterally similar in extent and appearance within affected family members but varied between affected family members. A total of six out of the seven affected female family members tested for hearing loss were diagnosed with otosclerosis and/or unilateral conductive hearing loss, including the proband's grandmother (II-4) age 45, aunty (III-3) age 40, aunty (III-5) age 36, female cousin (IV-6) age 14, female cousin (IV-8) age 20 and niece (V-1) age 5, with evidence of deterioration with age. The only female tested that was negative for hearing loss was the proband, age 27 years (Figure 1).

All four of the affected family members reviewed here in detail (Table 1) presented with progressive postnatal acquisition of vertebral fusions (Figure 4). Ultrasound before birth for two affected family members (IV-12 and V-3) confirmed the absence of congenital vertebral fusion which later developed postnatally through progressive ossification. Vertebral fusion, carpal and tarsal coalition, bilateral pisiform elongation and vocal impairment were all variable in extent between affected family members. Bilateral deviation of the proximal phalanges of toes 2-5 was evident in two affected female members of the family (IV-8, see Figure 4r) and (III-2, see Figure 4s). The former female's mother (III-5) developed painful age-related bilateral spurs on the patella at age 65 (Figure 4t) and age-related conductive hearing impairment age 40. Other skeletal anomalies included Perthes of the hip in one teenage male in association with a minimal fusion bridge between the C2-3 vertebrae and no obvious speech impairment (V-3). There was no evidence of restriction of the elbows or the shoulders in affected family members. Most affected family members presented with varying degrees of speech impairment from a young age in association with malformation of laryngeal cartilages including flattening of the anterior commissure and shortening of the vocal cords [15]. Surgical intervention in one affected family member reported that the vocal cords were shorter, failed to meet in the midline, were of a different complexion/composition and did not vibrate normally and that other vocal ligaments were ossified [15]. Short tongue and microstomia with overcrowding of the teeth were common. In more severely speech-affected members of the family there were deficits in verbal fluency and significant difficulty in generating words beginning with a certain letter [15]. Stature and intelligence appeared within the normal limits for all affected family members. Speech and hearing impairment affected learning; pisiform expansion restricted wrist rotation supination and grasping and capacity to write; narrowing of the oesophageal and laryngeal canals restricted swallowing and anaesthetic intubation; Achilles tendon stiffness was associated with toe walking; and arthritis progressed with age in many of the affected family members.

### 3.2. Gene Expression Analyses

#### 3.2.1. Comparative rtPCR Gene Expression Analysis

RNA isolated from fresh white blood cells derived from two severely affected family members (III-6 and IV-10) and five unaffected control individuals were analysed for changes in *GDF6* expression using comparative rtPCR expression analysis (Figure 5). *GDF6* expression levels were reduced in both affected family members when compared to the mean expression level for the five unaffected control individuals (Figure 5).



**Figure 5.** Comparative rtPCR analysis of *GDF6* expression in SYNS4 family. *GDF6* expression levels in fresh white blood cells expressed as the mean percentage change for two affected male members of the family compared with the mean for five age- and gender-matched unaffected controls independently normalised against the expression of two housekeeping reference genes *GAPDH* and *18sRNA*.

#### 3.2.2. RNA Sequencing Gene Expression Analysis (RNAseq)

RNA isolated from a severely affected family member with reduced *GDF6* expression (III-6) was used for RNAseq gene expression analysis. RNAseq analysis identified 68 and 61 genes with >10 fold differential gene expression in primary fibroblast cultures and fresh white blood cells, respectively ( $p < 0.05$ ) (Table 3). Of these, 3 genes (*NOMO3*, *RBMXL1* and *NEIL2*) exhibited >10 fold knockdown in both primary fibroblasts and white blood cells from the affected family member compared with an age, gender and racially matched unaffected control individual (Table 3).

**Table 3.** Differentially expressed genes in RNA sequence analysis.

Fibroblast Cell Lines				White Blood Cells			
Down-Regulation		Up-Regulation		Down-Regulation		Up-Regulation	
Change	Gene	Change	Gene	Change	Gene	Change	Gene
−15.3854	NOMO3 *	10.4092	MDGA1	−15.077	AK4	11.0154	TMEM201
−15.0439	DNAH1	11.4755	GMEB1	−15.0329	GPR68	11.1429	ARNTL
−14.9457	PRDM10	11.9372	CSTF2	−14.6255	CDK19	11.8143	SLC25A38
−14.7973	IDO1	12.1726	RPGRIP1	−14.4338	PHETA1	11.8187	ADARB1
−14.7586	SP140L	12.301	TRIT1	−14.2377	ABHD16B	12.0527	ZCCHC4
−14.6305	MYSM1	12.4321	ADGRA2	−14.0202	ZNF229	12.1243	BBS5
−14.5996	GRB10	12.5031	PCGF1	−13.9483	TSC1	12.1532	UCP2
−14.4498	PTGS2BLOC1S2	12.5352	GAL3ST4	−13.9278	BTBD3	12.1681	ATP6V0A1
−14.1642	TMEM260	12.7603	POM121	−13.7308	TMEM134	12.3948	CEP83
−14.0789	SNX13	12.833	HTATIP2	−13.6908	AFMID	12.4649	NMNAT1
−14.0487	RCBTB1	12.9472	PHETA1	−13.6735	LIG1	12.6268	TMEM209
−14.0126	CCP110	13.1595	MAP2K6	−13.2039	GRAMD1A	12.6402	IQCE
−13.7795	RBMXL1 *	13.1675	AP5S1	−12.9068	TRIT1	12.8589	PHTF1
−13.7398	EPHX2	13.2051	TBP	−12.7789	ZBTB43	13.0328	UBL4A
−13.6138	NF2	13.2154	KIAA023	−12.676	MTR	13.0354	GOLPH3L
−13.3585	GZF1	13.2714	2	−12.624	NOMO3 *	13.0485	MED19
−13.2922	CDCA8	13.276	ZNF550	−12.6236	RBMXL1 *	13.0628	GLI2
−13.2741	AMZ2	13.3216	SOCS2	−12.603	RPF2	13.086	XKR8
−13.2696	POLR1B	13.3411	ZNF280D	−12.5258	SP100	13.1499	ZBED8
−13.2425	TTI1	13.7474	EML3	−12.4878	KRBA1	13.1582	SCML1
−13.2212	WDR19	13.7502	FECH	−12.4472	MORC2	13.2509	NEDD9
−13.1889	ABCB7	14.072	GZF1	−12.1771	UBE2F	13.2561	ROR1
−13.1802	SMC6	14.0828	ZNF331	−12.1662	LRRN3	13.3067	ZC3H8
−13.104	DERA	14.1284	DAG1	−12.0355	MAP3K4	13.3068	CEP44
−12.7709	ZNF33B	14.1698	MKS1	−11.5972	NEIL2 *	13.3209	ZNF274
−12.6132	POLR3B	14.341	AKAP7	−11.497	EPHA4	13.4586	POGZ
−11.8528	NEIL2 *	14.5617	COG6	−11.2932	NT5M	13.617	TENT5A
−11.8236	BEGAIN	14.7657	ZNF302	−11.0185	REEP2	13.6751	TNIK
−11.801		14.7712	PAX5	−10.4318	ZFYVE27	13.8247	TOP3A
		14.8012	ZNF628			13.8448	BTRC
		15.2457	ZNF133			13.9705	INPP4A
		15.7457	POT1			14.1731	PIK3R1
		16.0123	ZNF57			14.3364	ELAPOR2
			CACNB3			14.5402	NAV3
						14.8302	GALNT15
						14.9429	NUP155
						15.0595	ADGRB2
						15.5187	SLC4A3
						15.8286	MPDZ
						16.3832	ZNF510

\* Genes downregulated in both fibroblast cell lines and fresh white blood cells.

#### 4. Discussion

In this study we report the first SYNS4 family with reduced *GDF6* expression. The three previously reported SYNS4 families had *GDF6* gain-of-function mutations [3–5]. The family phenotype included the classical bilateral carpal and tarsal coalition and otosclerosis associated conductive hearing loss typical of SYNS4 [3–5]. In addition, there was progressive postnatal acquisition of vertebral fusions in the cervical and thoracic spine from an early age. The extent of the vertebral fusion was variable between affected family members; notwithstanding, all affected family members displayed some degree of fusion across the C2-3 vertebral interspace at the cranial end of the cervical spine. Most affected family members were also speech impaired in association with malformation of the laryngeal cartilages and what appeared to be progressive ossification of laryngeal ligaments and joints.

The decrease in *GDF6* expression in this family was associated with a chromosomal breakpoint 3' of the *GDF6* gene [13]. *GDF6* encodes a bone morphogenetic protein which functions in a dose-dependent fashion in its extracellular regulation of skeletal development [1,16]. In consequence, the varying degrees of joint ossification and skeletal deformation in this family likely reflect variations in the reduction of *GDF6* dose at different skeletal sites in different affected family members, possibly due to position effects on *GDF6* regulatory elements located near the chromosomal breakpoint. Indeed, a conserved long-range *GDF6* pharyngeal specific enhancer (ECR5) that functions from the earliest stages of pharyngeal and otolaryngeal development has been located between *GDF6* and the chromosomal breakpoint in this family [1,17].

Otosclerosis-associated conductive hearing loss represents one of the classical acquired characteristics of SYSN4 [3–5]. In this family, otosclerotic hearing loss presented at varying ages (5–40 years of age) in affected females only, but not in affected males. This finding would appear to indicate a gender effect on the progressive ossification of the ossicles in this family. In contrast, speech impairment in this family was associated with congenital malformation and aberrant postnatal ossification of the larynx which was more severe in males compared to females and further exacerbated during descent of the thyroid cartilage during male puberty. Notwithstanding, the one affected male member of the family without speech impairment (V-3) also displayed the least degree of vertebral fusion.

*Gdf6* is expressed in discrete patterns within the developing joints of the mouse [1,2]. These same joints correspond precisely with those joints that were fused and malformed in the affected family including the joints of the carpals, tarsals, vertebrae, ear and larynx [1,2]. Moreover, knockout of *Gdf6* in mice results in the fusion of the carpals and tarsals but not the vertebrae [1]. This study identifies the biological basis of vertebral fusion in this family as aberrant progressive postnatal ossification and synostosis of the spinal joints from an early age. This mechanism is comparable and consistent with the aberrant postnatal ossification within the inner ear causing otosclerosis in SYNS4 [3–5]. In contrast, the precise mechanism of the carpal and tarsal fusions in this family remains uncertain. Notwithstanding, the bilateral symmetry of the carpal, tarsal and pisiform fusions/malformations within affected family members appears more consistent with a prenatal error of development, possibly effecting aberrant and excessive bone condensation/ossification prenatally. This fusion scenario is supported by animal studies which indicate a role for *Gdf6* in stimulating chondrogenesis at early stages of development [16] while in vitro studies indicate that *GDF6* has a distinct inhibitory effect on ossification and mineralization at later-stage, differentiated chondrocytes or osteoblasts [18]. *GDF6* is a bone morphogenetic protein that acts extracellularly as a morphogen during development. Albeit the pathway down stream of *GDF6* in determining cell fate and function has not been fully elucidated [3–5]. For insight into this pathway we searched for changes in gene expression in a severely affected family member (III-6) with reduced *GDF6* expression (Figure 5 and Table 3). RNAseq expression analysis identified >10 fold knockdown of three genes, *NOMO3*, *RBMXL1* and *NEIL2*, in both primary fibroblast cultures and fresh white blood cells from this severely affected family member (Table 3) [19–22]. This limited but close correlation in differential gene expression between disparate cell types provides a high level of confidence with respect to ongoing pathway and gene therapy investigations, not only in these three genes but the other genes differentially expressed in this patient (Table 3). It is therefore likely that one or more of these down-regulated genes has a role in the *GDF6* pathway to skeletal joint development and ossification. *RBMXL1* is of particular interest as it strengthens DNA heterochromatin binding, impedes the activity of transcription factors, suppresses gene transcription and serves as a barrier to direct cell conversion. Knockdown of *RBMXL1* increases gene transcription [19]. *NOMO3* is another molecule of interest as it is a positive modulator of the morphogen *Nodal* which is down regulated >5 fold in patients with facial asymmetry and jaw malformations. *Nodal* is a transcription factor regulated by asymmetric cascades of morphogens. *Nodal* initiates the molecular pathway that induces

chirality and asymmetry in endoderm and mesoderm germ layers during late gastrulation and neurulation [20,23].

## 5. Conclusions

Prenatal ultrasound followed with long-term radiological evaluation of the skeleton helped to differentiate between congenital, acquired, postnatal and progressive skeletal ossification and associated skeletal malformations. This study indicates a role for *GDF6* in the prenatal development of the joints of the hands and feet and larynx and in the progressive postnatal ossification of the joints of the inner ear, larynx and vertebral column. These findings further suggest that all *GDF6*-associated vertebral fusions may result from aberrant postnatal ossification, including those vertebral fusions previously assumed but never proven to be congenital errors of segmentation [10,13].

**Author Contributions:** Conceptualization, R.A.C.; methodology, R.A.C. and Z.F.; formal analysis, R.A.C. and Z.F.; investigation, R.A.C.; resources, D.M., T.S. and V.E.; data curation, Z.F.; writing—original draft preparation, R.A.C.; writing—review and editing, R.A.C.; supervision, R.A.C., D.M., V.E.; project administration, R.A.C. and V.E.; funding acquisition, R.A.C. and V.E. All authors have read and agreed to the published version of the manuscript.

**Funding:** Australian National Health and Medical Research Council (NHMRC) Grant ID-970859. Scoliosis Research Society (USA) Grant ID-30999.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the University of New South Wales Human Ethics Committee (Approval Number: H8853).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** please refer to suggested Data Availability Statements in section “MDPI Research Data Policies” at <https://www.mdpi.com/ethics>.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

- Settle, S.H.; Rountree, R.B.; Sinha, A.; Thacker, A.; Higgins, K.; Kingsley, D.M. Multiple joint and skeletal patterning defects caused by single and double mutations in the mouse *Gdf6* and *Gdf5* genes. *Dev. Biol.* **2003**, *254*, 116–130. [CrossRef]
- Mortlock, D.P.; Guenther, C.; Kingsley, D.M. A General Approach for Identifying Distant Regulatory Elements Applied to the *Gdf6* Gene. *Genome Res.* **2003**, *13*, 2069–2081. [CrossRef]
- Wang, J.; Yu, T.; Wang, Z.; Ohte, S.; Yao, R.-E.; Zheng, Z.; Geng, J.; Cai, H.; Ge, Y.; Li, Y.; et al. A New Subtype of Multiple Synostoses Syndrome Is Caused by a Mutation in *GDF6* That Decreases Its Sensitivity to Noggin and Enhances Its Potency as a BMP Signal. *J. Bone Miner. Res.* **2016**, *31*, 882–889. [CrossRef]
- Terhal, P.A.; Verbeek, N.E.; Knoers, N.; Nievelstein, R.J.A.J.; Ouweland, A.V.D.; Sakkars, R.J.; Speleman, L.; Van Haaften, G. Further delineation of the *GDF6* related multiple synostoses syndrome. *Am. J. Med. Genet. Part A* **2018**, *176*, 225–229. [CrossRef] [PubMed]
- Berentsen, R.D.; Haukanes, B.I.; Júlíusson, P.B.; Rosendahl, K.; Houge, G. A Novel *GDF6* Mutation in a Family with Multiple Synostoses Syndrome without Hearing Loss. *Mol. Syndr.* **2018**, *9*, 228–234. [CrossRef]
- Schwaerzer, G.K.; Hiepen, C.; Schrewe, H.; Nickel, J.; Ploeger, F.; Sebald, W.; Mueller, T.; Knaus, P. New insights into the molecular mechanism of multiple synostoses syndrome (SYNS): Mutation within the *GDF5* knuckle epitope causes noggin-resistance. *J. Bone Miner. Res.* **2011**, *27*, 429–442. [CrossRef]
- Dawson, K.; Seeman, P.; Sebald, E.; King, L.; Edwards, M.; Williams, J.; Mundlos, S.; Krakow, D. *GDF5* Is a Second Locus for Multiple-Synostosis Syndrome. *Am. J. Hum. Genet.* **2006**, *78*, 708–712. [CrossRef]
- Seemann, P.; Brehm, A.; König, J.; Reissner, C.; Stricker, S.; Kuss, P.; Haupt, J.; Renninger, S.; Nickel, J.; Sebald, W.; et al. Mutations in *GDF5* Reveal a Key Residue Mediating BMP Inhibition by *NOGGIN*. *PLoS Genet.* **2009**, *5*, e1000747. [CrossRef] [PubMed]
- Yang, W.; Cao, L.; Liu, W.; Jiang, L.; Sun, M.; Zhang, D.; Wang, S.; Lo, W.H.Y.; Luo, Y.; Zhang, X. Novel point mutations in *GDF5* associated with two distinct limb malformations in Chinese: Brachydactyly type C and proximal symphalangism. *J. Hum. Genet.* **2008**, *53*, 368–374. [CrossRef]
- Asai-Coakwell, M.; French, C.R.; Ye, M.; Garcha, K.; Bigot, K.; Perera, A.G.; Staehling-Hampton, K.; Mema, S.; Chanda, B.; Mushegian, A.; et al. Incomplete penetrance and phenotypic variability characterize *Gdf6*-attributable oculo-skeletal phenotypes. *Hum. Mol. Genet.* **2009**, *18*, 1110–1121. [CrossRef]

11. Ye, M.; Berry-Wynne, K.M.; Asai-Coakwell, M.; Sundaresan, P.; Footz, T.; French, C.R.; Abitbol, M.; Fleisch, V.C.; Corbett, N.; Allison, T.; et al. Mutation of the bone morphogenetic protein GDF3 causes ocular and skeletal anomalies. *Hum. Mol. Genet.* **2009**, *19*, 287–298. [[CrossRef](#)] [[PubMed](#)]
12. Banka, S.; Cain, S.A.; Carim, S.; Daly, S.B.; Urquhart, J.; Erdem, G.; Harris, J.; Bottomley, M.; Donnai, D.; Kerr, B.; et al. Leri's pleonosteosis, a congenital rheumatic disease, results from microduplication at 8q22.1 encompassing GDF6 and SDC2 and provides insight into systemic sclerosis pathogenesis. *Ann. Rheum. Dis.* **2014**, *74*, 1249–1256. [[CrossRef](#)]
13. Clarke, R.; Singh, S.; McKenzie, H.; Kearsley, J.H.; Yip, M.Y. Familial Klippel-Feil syndrome and paracentric inversion inv(8)(q22.2q23.3). *Am. J. Hum. Genet.* **1995**, *57*, 1364–1370.
14. Fang, Z.; Eapen, V.; Clarke, R.A. CTNNA3 discordant regulation of nested LRRTM3, implications for autism spectrum disorder and Tourette syndrome. *Meta Gene* **2017**, *11*, 43–48. [[CrossRef](#)]
15. Clarke, R.A.; Davis, P.J.; Tonkin, J. Klippel-Feil Syndrome Associated with Malformed Larynx. Case report. *Ann. Otol. Rhinol. Laryngol.* **1994**, *103*, 201–207. [[CrossRef](#)]
16. Pregizer, S.; Mortlock, D.P. Control of BMP gene expression by long-range regulatory elements. *Cytokine Growth Factor Rev.* **2009**, *20*, 509–515. [[CrossRef](#)] [[PubMed](#)]
17. Reed, N.P.; Mortlock, D.P. Identification of a distant cis-regulatory element controlling pharyngeal arch-specific expression of zebrafish *gdf6a*/radar. *Dev. Dyn.* **2010**, *239*, 1047–1060. [[CrossRef](#)] [[PubMed](#)]
18. Shen, B.; Bhargav, D.; Wei, A.; Williams, L.; Tao, H.; Ma, D.D.F.; Diwan, A. BMP-13 Emerges as a Potential Inhibitor of Bone Formation. *Int. J. Biol. Sci.* **2009**, *5*, 192–200. [[CrossRef](#)]
19. Becker, J.; McCarthy, R.L.; Sidoli, S.; Donahue, G.; Kaeding, K.; He, Z.; Lin, S.; Garcia, B.A.; Zaret, K.S. Genomic and Proteomic Resolution of Heterochromatin and Its Restriction of Alternate Fate Genes. *Mol. Cell* **2017**, *68*, 1023–1037.e15. [[CrossRef](#)]
20. Nicot, R.; Hottenstein, M.; Raoul, G.; Ferri, J.; Horton, M.; Tobias, J.W.; Barton, E.; Gelé, P.; Sciote, J.J. Nodal Pathway Genes Are Down-regulated in Facial Asymmetry. *J. Craniofacial Surg.* **2014**, *25*, e548–e555. [[CrossRef](#)]
21. Scheffler, K.; Jalland, C.M.; Benestad, S.L.; Moldal, T.; Ersdal, C.; Gunnes, G.; Suganthan, R.; Bjørås, M.; Tranulis, M.A. DNA glycosylase Neil2 contributes to genomic responses in the spleen during clinical prion disease. *Free. Radic. Biol. Med.* **2020**, *152*, 348–354. [[CrossRef](#)] [[PubMed](#)]
22. Sarker, A.H.; Chatterjee, A.; Williams, M.; Lin, S.; Havel, C.; Iii, P.J.; Boldogh, I.; Hazra, T.K.; Talbot, P.; Hang, B. NEIL2 Protects against Oxidative DNA Damage Induced by Sidestream Smoke in Human Cells. *PLoS ONE* **2014**, *9*, e90261. [[CrossRef](#)] [[PubMed](#)]
23. Vandenberg, L.N.; Levin, M. A unified model for left–right asymmetry? Comparison and synthesis of molecular models of embryonic laterality. *Dev. Biol.* **2013**, *379*, 1–15. [[CrossRef](#)] [[PubMed](#)]